Published online
doi:10.1084/jem.20070828
The Journal of Experimental Medicine, Vol. 204, No. 9, 2053-2061
The Rockefeller University Press, 0022-1007 $30.00
© Ghosh et al.
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR
activation
Mallika Ghosh1,
Haibin Wang2,3,4,
Youxi Ai1,
Elisa Romeo5,
James P. Luyendyk5,
Jeffrey M. Peters6,7,
Nigel Mackman5,
Sudhansu K. Dey2,3,4, and
Timothy Hla1
1 Center for Vascular Biology, Department of Cell Biology, University of Connecticut Health Center, Farmington, CT 06030
2 Departments of Pediatrics, 3 Cell and Developmental Biology, and 4 Pharmacology, Division of Reproductive and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37232
5 Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
6 Department of Veterinary Science and 7 Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802
CORRESPONDENCE Timothy Hla: hla{at}nso2.uchc.edu
Although cyclooxygenase (COX)-2 inhibitors (coxibs) are effective in controlling inflammation, pain, and tumorigenesis, their use is limited by the recent revelation of increased adverse cardiovascular events. The mechanistic basis of this side effect is not well understood. We show that the metabolism of endocannabinoids by the endothelial cell COX-2 coupled to the prostacyclin (PGI2) synthase (PGIS) activates the nuclear receptor peroxisomal proliferator–activated receptor (PPAR)
, which negatively regulates the expression of tissue factor (TF), the primary initiator of blood coagulation. Coxibs suppress PPAR
activity and induce TF expression in vascular endothelium and elevate circulating TF activity in vivo. Importantly, PPAR
agonists suppress coxib-induced TF expression and decrease circulating TF activity. We provide evidence that COX-2–dependent attenuation of TF expression is abrogated by coxibs, which may explain the prothrombotic side-effects for this class of drugs. Furthermore, PPAR
agonists may be used therapeutically to suppress coxib-induced cardiovascular side effects.
Abbreviations used: AA, arachidonic acid; AEA, anandamide; AG, arachidonyl glycerol; COX, cyclooxygenase; EC, endothelial cell; HUVEC, human umbilical vein EC; NE, noladin ether; PGFS, PGF2
synthase; PGI2, prostacyclin; PGIS, PGI2 synthase; PPAR, peroxisomal proliferator–activated receptor; PPP, platelet poor plasma; q, quantitative; TF, tissue factor; VSA, valeryl salicylate.
The Rockefeller University Press

CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
-
Seta, F., Chung, A. D., Turner, P. V., Mewburn, J. D., Yu, Y., Funk, C. D.
(2009). Renal and cardiovascular characterization of COX-2 knockdown mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.
296: R1751-R1760
[Abstract]
[Full Text]
-
DuBois, R. N.
(2009). New, Long-term Insights from the Adenoma Prevention with Celecoxib Trial on a Promising but Troubled Class of Drugs. Cancer Prevention Research
2: 285-287
[Full Text]
-
Rouzer, C. A., Marnett, L. J.
(2009). Cyclooxygenases: structural and functional insights. J. Lipid Res.
50: S29-S34
[Abstract]
[Full Text]
-
Bility, M. T., Devlin-Durante, M. K., Blazanin, N., Glick, A. B., Ward, J. M., Kang, B. H., Kennett, M. J., Gonzalez, F. J., Peters, J. M.
(2008). Ligand activation of peroxisome proliferator-activated receptor {beta}/{delta} (PPAR{beta}/{delta}) inhibits chemically induced skin tumorigenesis. Carcinogenesis
29: 2406-2414
[Abstract]
[Full Text]
-
Rouzer, C. A., Marnett, L. J.
(2008). Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids. J. Biol. Chem.
283: 8065-8069
[Abstract]
[Full Text]